Temozolomide

• UNSPSC Description:

  Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].

• Target Antigen:

  Apoptosis; Autophagy; DNA Alkylator/Crosslinker

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Temozolomide.html

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic)|H2O : 2.86 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(N2C=N1)N=NN(C)C2=O)N

• Molecular Weight:

  194.154

• References & Citations:

  [1]Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.|[2]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.|[3]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10(12):1383-92.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  85622-93-1